The p53-Estrogen Receptor Loop in Cancer

被引:67
作者
Berger, C. [1 ]
Qian, Y. [1 ]
Chen, X. [1 ]
机构
[1] Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA
关键词
Estrogen receptor; hormone-dependent cancer; p53; transcription factors; HUMAN-PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; POSITIVE BREAST-CANCER; P53; GENE-EXPRESSION; ER-BETA; COLON-CANCER; CELL-CYCLE; ALPHA EXPRESSION; ENDOMETRIAL CANCER; CERVICAL-CANCER;
D O I
10.2174/15665240113139990065
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tumor suppressor p53 maintains genome stability by regulating diverse cellular functions including cell cycle arrest, apoptosis, senescence and metabolic homeostasis. Mutations in the p53 gene occur in almost all human cancers with a frequency of up to 80%. However, it is only 20% in breast cancers, 18% in endometrial cancers and 1.5% in cervical cancers. Estrogen receptor alpha (ER alpha) plays a pivotal role in hormone-dependent cancer development and the status of ER alpha is used for designing treatment strategy and for prognosis. A closer look at the cross-talk between p53 and ER alpha has revealed that their activities are mutually regulated. This review will summarize the current body of knowledge on p53, ER alpha and ER beta in cancer. Clinical correlations between estrogen receptors and p53 status have also been reported. Thus, this review will discuss the relationship between p53 and ERs at both the molecular and clinical levels.
引用
收藏
页码:1229 / 1240
页数:12
相关论文
共 149 条
  • [1] Regulation of estrogen receptor-α expression by the tumor suppressor gene p53 in MCF-7 cells
    Angeloni, SV
    Martin, MB
    Garcia-Morales, P
    Castro-Galache, MD
    Ferragut, JA
    Saceda, M
    [J]. JOURNAL OF ENDOCRINOLOGY, 2004, 180 (03) : 497 - 504
  • [2] EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY
    ARCHER, SG
    ELIOPOULOS, A
    SPANDIDOS, D
    BARNES, D
    ELLIS, IO
    BLAMEY, RW
    NICHOLSON, RI
    ROBERTSON, JFR
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (05) : 1259 - 1266
  • [3] Inhibition of growth of cervical cancer cells using a dominant negative estrogen receptor gene
    Au, William W.
    Abdou-Salama, Salama
    Al-Hendy, Ayman
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 104 (02) : 276 - 280
  • [4] Estrogen receptor prevents p53-dependent apoptosis in breast cancer
    Bailey, Shannon T.
    Shin, Hyunjin
    Westerling, Thomas
    Liu, Xiaole Shirley
    Brown, Myles
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (44) : 18060 - 18065
  • [5] Enhanced phosphorylation of p53 by ATN in response to DNA damage
    Banin, S
    Moyal, L
    Shieh, SY
    Taya, Y
    Anderson, CW
    Chessa, L
    Smorodinsky, NI
    Prives, C
    Reiss, Y
    Shiloh, Y
    Ziv, Y
    [J]. SCIENCE, 1998, 281 (5383) : 1674 - 1677
  • [6] Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-β-dependent pathways
    Becker, KA
    Lu, SL
    Dickinson, ES
    Dunphy, KA
    Mathews, L
    Schneider, SS
    Jerry, DJ
    [J]. ONCOGENE, 2005, 24 (42) : 6345 - 6353
  • [7] Prognostic effect of estrogen receptor status across age in primary breast cancer
    Bentzon, Niels
    Duering, Maria
    Rasmussen, Birgitte Bruun
    Mouridsen, Henning
    Kroman, Niels
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (05) : 1089 - 1094
  • [8] p53, a Target of Estrogen Receptor (ER) α, Modulates DNA Damage-induced Growth Suppression in ER-positive Breast Cancer Cells
    Berger, Crystal E.
    Qian, Yingjuan
    Liu, Gang
    Chen, Hongwu
    Chen, Xinbin
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (36) : 30117 - 30127
  • [9] COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY
    BERGH, J
    NORBERG, T
    SJOGREN, S
    LINDGREN, A
    HOLMBERG, L
    [J]. NATURE MEDICINE, 1995, 1 (10) : 1029 - 1034
  • [10] Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
    Bergman, L
    Beelen, MLR
    Gallee, MPW
    Hollema, H
    Benraadt, J
    van Leeuwen, FE
    [J]. LANCET, 2000, 356 (9233) : 881 - 887